The Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended that the oral Janus kinase 1 inhibitor abrocitinib be granted marketing authorization in the European Union for treating atopic dermatitis (AD). The full indication is for the…
Read More
Upadacitinib Effective and Safe in Atopic Dermatitis at 52 Weeks
Upadacitinib (Rinvoq, AbbVie) in combination with topical corticosteroids is safe and effective for the treatment of moderate to severe atopic dermatitis in adolescents and adults out to 52 weeks, and it is superior to the biologic drug dupilumab (Dupixent), according…
Read More
Trial results show upadacitinib to be the most effective treatment for atopic dermatitis
The findings of a clinical trial by Trinity College Dublin researchers of treatment for atopic dermatitis have been published today in The Lancet journal (Friday, 21st May, 2021). Results of the clinical trial at the School of Medicine, Trinity College…
Read More
What Drives Treatment Satisfaction Among Adults With AD?
Atopic dermatitis (AD) is associated with lower patient satisfaction scores in adults, suggesting there are unmet needs in clinical AD management. Satisfaction scores were higher when specialists prescribed systemic therapy, but were lower when nonspecialists prescribed systemic therapy and when…
Read More